Compare Danaher Corporation (DHR) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Danaher Corporation trades at $198.81 (market cap $140.88B), while iShares 7-10 Year Treasury Bond ETF trades at $93.61. The key difference: Danaher Corporation pays a 0.8% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and Danaher Corporation is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| DHR | IEF | |
|---|---|---|
Market Cap | $140.88B | — |
Sector | Health | — |
52-Week High | $242.05 | $97.99 |
52-Week Low | $161.91 | $93.11 |
Enterprise Value | $153.66B | — |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
IEF trades at $93.29, down 0.36% on the day, with a bearish technical signal driven by moving averages. The ETF shows neutral oscillators but oversold short-term RSI. Recent news highlights bond ETF inflows and investor focus on yield amid Federal Reserve uncertainty, with articles from Benzinga (July 14, 2026) and CNBC (June 25, 2026) noting record flows and rate hike speculation.
Outlook remains cautious due to interest rate sensitivity and macroeconomic pressures. Risks include potential Fed hikes and inflation concerns, but the oversold RSI may offer short-term support. Investors should weigh yield attractiveness against duration risk in the current rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
